Abstract
Background:
In the treatment of hypertension, combination therapy is important10 because antihypertensive monotherapy is effective in only 40% of patients worldwide. Amlodipine is a dihydropyridine calcium channel blocker with a slow onset and long duration of action. Benazepril hydrochloride is a prodrug hydrolyzed by esterase to the active metabolite benazeprilat, an angiotensin-converting enzyme inhibitor. In 1995, the US Food and Drug Administration approved the use of a capsule formulation of combination amlodipine-benazepril for hypertension.
Objective:
The aim of this study was to compare the bioavailability and tolerability10 of the capsule formulation with those of a tablet formulation of combination amlodipine-benazepril in healthy volunteers.
Methods:
This single-dose, 2-sequence, 2-period, open-label, crossover10 study recruited healthy, adult, male volunteers with normotension. Subjects were randomly assigned to 1 of 2 treatment sequences: a single-dose tablet containing amlodipine 5 mg plus benazepril 10 mg, followed by a single-dose capsule containing the same dose of each drug (AB), or vice versa (BA). The treatment period for each drug consisted of dosing and pharmacokinetic analysis on day 1, followed by pharmacokinetic analysis on days 2 to 7. Treatment periods were separated by a 4-week washout period. For pharmacokinetic analysis, serial blood samples were obtained before dosing and at 20, 40, 60, 80, and 100 minutes and 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 36, 60, 84, 108, 132, and 156 hours after dosing. Tolerability was assessed using subject interview and spontaneous reporting.
Results:
Twelve healthy, male, Taiwanese subjects (mean [SD] age, 23.510 [1.7] years) participated in the study. No statistically significant differences inbioavailability were found between the 2 formulations based on the pharmacokinetic measurements of amlodipine and benazeprilat. The rate and extent of absorption of the tablets were found to be comparable to those of the capsules (90% CI, between 80% and 125%). The mean (SD) relative bioavailabilities, as represented by AUC0−∞, of amlodipine and benazeprilat for tablets versus capsules were 1.060 (0.170) versus 0.949 (0.197), respectively. The mean plasma concentration-time profiles of amlodipine and benazeprilat were graphically similar. No adverse effects were observed with either formulation.
Conclusions:
The results of this bioavailability comparison study in this 10 population of healthy, male, Taiwanese volunteers suggest that the tablet and capsule formulations of combination amlodipine-benazepril are bioequivalent. Both formulations were well tolerated.
Key words: bioequivalence, bioavailability, pharmacokinetics, amlodipinebesylate, benazepril hydrochloride, fixed-dose combination
Full Text
The Full Text of this article is available as a PDF (585.0 KB).
References
- 1.Guidelines Subcommittee World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens. 1999;17:151–183. [PubMed] [Google Scholar]
- 2.Chobanian A.V., Bakris G.L., Black H.R., Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252. doi: 10.1161/01.HYP.0000107251.49515.c2. [DOI] [PubMed] [Google Scholar]
- 3.Lees K.R., Meredith P.A., Reid J.L. A clinical pharmacological study of nifedipine and lisinopril alone and in combination. J Cardiovasc Pharmacol. 1987;10(Suppl 10):S105–S107. [PubMed] [Google Scholar]
- 4.Jakobsen J., Glaus L., Graf P. Unmasking of the hypotensive effect of nifedipine in normotensives by addition of the angiotensin converting enzyme inhibitor benazepril. J Hypertens. 1992;10:1045–1051. [PubMed] [Google Scholar]
- 5.Brunel P., Guyene T.T., Howald H., Menard J. Arterial and endocrine effects of a combination of an angiotensin converting enzyme inhibitor and a vasodilator in normotensive healthy volunteers. J Cardiovasc Pharmacol. 1991;18:175–181. doi: 10.1097/00005344-199108000-00001. [DOI] [PubMed] [Google Scholar]
- 6.Meredith P.A., Elliott H.L. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet. 1992;22:22–31. doi: 10.2165/00003088-199222010-00003. [DOI] [PubMed] [Google Scholar]
- 7.Balfour J.A., Goa K.L. Benazepril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and congestive heart failure. Drugs. 1991;42:511–539. doi: 10.2165/00003495-199142030-00008. [DOI] [PubMed] [Google Scholar]
- 8.Fogari R., Corea L., Cardoni O. Combined therapy with benazepril and amlodipine in the treatment of hypertension inadequately controlled by an ACE inhibitor alone. J Cardiovasc Pharmacol. 1997;30:497–503. doi: 10.1097/00005344-199710000-00014. [DOI] [PubMed] [Google Scholar]
- 9.Chow S.-C., Liu J., editors. Design and Analysis of Bioavailability and Bioequivalence Studies. 2nd ed. Marcel Dekker; New York: 2000. [Google Scholar]
- 10.Faulkner J.K., McGibney D., Chasseaud L.F. The pharmacokinetics of amlodipine in healthy volunteers after single intravenous and oral doses and after 14 repeated oral doses given once daily. Br J Clin Pharmacol. 1986;22:21–25. doi: 10.1111/j.1365-2125.1986.tb02874.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Sun J.X., Cipriano A., Chan K., John V.A. Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. Eur J Clin Pharmacol. 1994;47:285–289. doi: 10.1007/BF02570510. [DOI] [PubMed] [Google Scholar]
- 12.Kaiser G., Ackermann R., Sioufi A. Pharmacokinetics of a new angiotensin-converting enzyme inhibitor, benazepril hydrochloride, in special populations. Am Heart J. 1989;117:746–751. doi: 10.1016/0002-8703(89)90765-5. [DOI] [PubMed] [Google Scholar]
- 13.Williams D.M., Cubeddu L.X. Amlodipine pharmacokinetics in healthy volunteers. J Clin Pharmacol. 1988;28:990–994. doi: 10.1002/j.1552-4604.1988.tb03119.x. [DOI] [PubMed] [Google Scholar]
- 14.Abernethy D.R. Pharmacokinetics and pharmacodynamics of amlodipine. Cardiology. 1992;80(Suppl 1):31–36. doi: 10.1159/000175050. [DOI] [PubMed] [Google Scholar]
- 15.Kelly J.G., O'Malley K. Clinical pharmacokinetics of the newer ACE inhibitors. A review. Clin Pharmacokinet. 1990;19:177–196. doi: 10.2165/00003088-199019030-00003. [DOI] [PubMed] [Google Scholar]
- 16.Lotrel capsules (amlodipine and benazepril hydrochloride) [product information] Novartis Pharmaceuticals Corporation; East Hanover, NJ: 2000. [Google Scholar]